Tags

Type your tag names separated by a space and hit enter

Sulfobutyl ether(7) β-cyclodextrin (SBE(7) β-CD) carbamazepine complex: preparation, characterization, molecular modeling, and evaluation of in vivo anti-epileptic activity.
AAPS PharmSciTech. 2011 Dec; 12(4):1163-75.AP

Abstract

The objective of the present investigation was to study the ability of sulfobutyl ether(7)-β-cyclodextrin to form an inclusion complex with carbamazepine, an anti-epileptic drug with poor water solubility. The formation of the complex was carried out using the industrially feasible spray-drying method. The inclusion complex and physical mixtures were characterized by various techniques such as differential scanning calorimetry (DSC), infrared (IR), nuclear magnetic resonance (NMR), X-ray diffraction (XRD), and molecular modeling. The DSC, IR, and NMR studies confirmed the formation of an inclusion complex between carbamazepine and sulfobutyl ether(7) β-cyclodextrin whereas XRD studies indicated an amorphous nature of the inclusion complex. Molecular modeling studies disclosed different modes of interaction between carbamazepine and sulfobutyl ether(7) β-cyclodextrin with good correlation with experimental observations. The inclusion complex exhibited significantly higher in vitro dissolution profile as compared with pure carbamazepine powder. The in vivo anti-epileptic activity of carbamazepine/sulfobutyl ether(7) β-cyclodextrin complex was evaluated in pentylenetetrazole-induced convulsions model. The carbamazepine/sulfobutyl ether(7) β-cyclodextrin complex showed significantly higher anti-epileptic activity (p <0.01) as compared with that of carbamazepine suspension on oral administration.

Authors+Show Affiliations

Department of Pharmaceutics, Bombay College of Pharmacy, Kalina, Santacruz, Mumbai, India.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

21918921

Citation

Jain, Ankitkumar S., et al. "Sulfobutyl Ether(7) Β-cyclodextrin (SBE(7) β-CD) Carbamazepine Complex: Preparation, Characterization, Molecular Modeling, and Evaluation of in Vivo Anti-epileptic Activity." AAPS PharmSciTech, vol. 12, no. 4, 2011, pp. 1163-75.
Jain AS, Date AA, Pissurlenkar RR, et al. Sulfobutyl ether(7) β-cyclodextrin (SBE(7) β-CD) carbamazepine complex: preparation, characterization, molecular modeling, and evaluation of in vivo anti-epileptic activity. AAPS PharmSciTech. 2011;12(4):1163-75.
Jain, A. S., Date, A. A., Pissurlenkar, R. R., Coutinho, E. C., & Nagarsenker, M. S. (2011). Sulfobutyl ether(7) β-cyclodextrin (SBE(7) β-CD) carbamazepine complex: preparation, characterization, molecular modeling, and evaluation of in vivo anti-epileptic activity. AAPS PharmSciTech, 12(4), 1163-75. https://doi.org/10.1208/s12249-011-9685-z
Jain AS, et al. Sulfobutyl Ether(7) Β-cyclodextrin (SBE(7) β-CD) Carbamazepine Complex: Preparation, Characterization, Molecular Modeling, and Evaluation of in Vivo Anti-epileptic Activity. AAPS PharmSciTech. 2011;12(4):1163-75. PubMed PMID: 21918921.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Sulfobutyl ether(7) β-cyclodextrin (SBE(7) β-CD) carbamazepine complex: preparation, characterization, molecular modeling, and evaluation of in vivo anti-epileptic activity. AU - Jain,Ankitkumar S, AU - Date,Abhijit A, AU - Pissurlenkar,Raghuvir R S, AU - Coutinho,Evans C, AU - Nagarsenker,Mangal S, Y1 - 2011/09/15/ PY - 2011/04/27/received PY - 2011/09/02/accepted PY - 2011/9/16/entrez PY - 2011/9/16/pubmed PY - 2012/3/27/medline SP - 1163 EP - 75 JF - AAPS PharmSciTech JO - AAPS PharmSciTech VL - 12 IS - 4 N2 - The objective of the present investigation was to study the ability of sulfobutyl ether(7)-β-cyclodextrin to form an inclusion complex with carbamazepine, an anti-epileptic drug with poor water solubility. The formation of the complex was carried out using the industrially feasible spray-drying method. The inclusion complex and physical mixtures were characterized by various techniques such as differential scanning calorimetry (DSC), infrared (IR), nuclear magnetic resonance (NMR), X-ray diffraction (XRD), and molecular modeling. The DSC, IR, and NMR studies confirmed the formation of an inclusion complex between carbamazepine and sulfobutyl ether(7) β-cyclodextrin whereas XRD studies indicated an amorphous nature of the inclusion complex. Molecular modeling studies disclosed different modes of interaction between carbamazepine and sulfobutyl ether(7) β-cyclodextrin with good correlation with experimental observations. The inclusion complex exhibited significantly higher in vitro dissolution profile as compared with pure carbamazepine powder. The in vivo anti-epileptic activity of carbamazepine/sulfobutyl ether(7) β-cyclodextrin complex was evaluated in pentylenetetrazole-induced convulsions model. The carbamazepine/sulfobutyl ether(7) β-cyclodextrin complex showed significantly higher anti-epileptic activity (p <0.01) as compared with that of carbamazepine suspension on oral administration. SN - 1530-9932 UR - https://www.unboundmedicine.com/medline/citation/21918921/Sulfobutyl_ether_7__β_cyclodextrin__SBE_7__β_CD__carbamazepine_complex:_preparation_characterization_molecular_modeling_and_evaluation_of_in_vivo_anti_epileptic_activity_ L2 - https://dx.doi.org/10.1208/s12249-011-9685-z DB - PRIME DP - Unbound Medicine ER -